Latest News for JCRRF
HYOGO, Japan--(BUSINESS WIRE)--JCR announced that IZCARGO, an enzyme replacement therapy indicated for Hunter syndrome, received marketing authorization in the United Arab Emirates.
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development in the treatment of Alzheimer's…
HYOGO, Japan--(BUSINESS WIRE)--JCR presented new clinical data in a poster session at the 18th International Symposium on MPS and Related Lysosomal Diseases, held June 4-7, 2026.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for JCRRF.
Senate Trading
No Senate trades found for JCRRF.
U.S. House Trading
No House trades found for JCRRF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.